header logo image


Page 716«..1020..715716717718..730740..»

UK biotech PhoreMost to work with Otsuka on gene therapy projects – – pharmaphorum

January 21st, 2020 8:46 am

Building on an R&D tie-up with an Indian stem cell institution last year, UK biotech PhoreMost has begun a collaboration with Japans Otsuka working on several gene therapy projects.

Cambridge-based PhoreMost said it will use its next-generation phenotypic screening platform Siteseeker to identify novel targets for Otsukas therapeutics discovery programmes.

Novel targets identified will be further validated and characterised by Otsuka as part of its internal development pipeline, with an initial focus on gene therapy applications of identified targets.

Siteseeker looks at different protein shapes to find functionally active peptides that can be targeted by new therapies.

The technology looks at the entire proteome all of the proteins expressed in a live cell environment looking for druggable targets for a chosen disease.

Financial details of the agreement were not disclosed.

Dr Chris Torrance, CEO of PhoreMost, said: This collaboration with Otsuka is further recognition of the power of the Siteseeker approach to drive the identification of novel, druggable targets.

We are particularly excited to be exploring not only small molecule therapeutics but also gene therapy applications of our platform.

PhoreMost was one of two UK-based companies to receive funding from the government-backed agency Innovate UK to receive funding for small molecule research.

The 1 million funding was announced in 2018, and supported PhoreMost and the immune-oncology firm NeoPhore.

The companies won the funding as part of a competition organised by Innovate UK and funded by the UKs Biomedical Catalyst.

PhoreMost is also working with Indias Centre for Chemical Biology and Therapeutics, part of the Institute for Stem Cell Science and Regenerative Medicine (inStem).

The project began in July last year and, with funding from the Indian government, aims to create chemical tools that modulate novel classes of drug targets.

InStem is researching the genetic mechanisms of potency, differentiation and proliferation in human pluripotent cells.

It aims to examine diseases that can potentially be treated by stem cells.

See original here:
UK biotech PhoreMost to work with Otsuka on gene therapy projects - - pharmaphorum

Read More...

Regenerative Medicine Market Business Scenario 2020 | SWOT Analysis by Major Players- Organogenesis Osiris Therapeutics, Vericel Corporation, Stryker…

January 21st, 2020 8:46 am

New Jersey, United States, The report titled, Regenerative Medicine Market has been recently published by Verified Market Research.The report has offered exhaustive analysis of the Regenerative Medicine Market taking into consideration all the crucial aspects like growth factors, constraints, market developments, future prospects, and trends. Market researchers and industry experts have pointed out the key market trends and prospects that may impact the overall Regenerative Medicine Market growth. This will help players to leverage the opportunities to strengthen their position. Also, the report throws light on the important factors that are contributing to the Regenerative Medicine Market growth. Additionally, challenges and impeding factors that could hamper the growth of the Regenerative Medicine Market in the years to come are mentioned in the report.

Global Regenerative Medicine Market was valued at USD 19.10 Billion in 2018 and is expected to witness a growth of 22.72% from 2019-2026 and reach USD 98.10 Billion by 2026.

Request a Sample Copy of this report @https://www.verifiedmarketresearch.com/download-sample/?rid=7157&utm_source=FSA&utm_medium=003

Top 10 Companies in the Global Regenerative Medicine Market Research Report:

Global Regenerative Medicine Market: Competitive Landscape

Competitive landscape of a market explains strategies incorporated by key players of the market. Key developments and shift in management in the recent years by players has been explained through company profiling. This helps readers to understand the trends that will accelerate the growth of market. It also includes investment strategies, marketing strategies, and product development plans adopted by major players of the market. The market forecast will help readers make better investments.

Global Regenerative Medicine Market: Drivers and Restrains

This section of the report discusses various drivers and restrains that have shaped the global market. The detailed study of numerous drivers of the market enable readers to get a clear perspective of the market, which includes market environment, government policies, product innovations, breakthroughs, and market risks.

The research report also points out the myriad opportunities, challenges, and market barriers present in the Global Regenerative Medicine Market. The comprehensive nature of the information will help the reader determine and plan strategies to benefit from. Restrains, challenges, and market barriers also help the reader to understand how the company can prevent itself from facing downfall.

Global Regenerative Medicine Market: Segment Analysis

This section of the report includes segmentation such as application, product type, and end user. These segmentations aid in determining parts of market that will progress more than others. The segmentation analysis provides information about the key elements that are thriving the specific segments better than others. It helps readers to understand strategies to make sound investments. The Global Regenerative Medicine Market is segmented on the basis of product type, applications, and its end users.

Global Regenerative Medicine Market: Regional Analysis

This part of the report includes detailed information of the market in different regions. Each region offers different scope to the market as each region has different government policy and other factors. The regions included in the report are North America, South America, Europe, Asia Pacific, and the Middle East. Information about different region helps the reader to understand global market better.

Ask for Discount @https://www.verifiedmarketresearch.com/ask-for-discount/?rid=7157&utm_source=FSA&utm_medium=003

Table of Content

1 Introduction of Regenerative Medicine Market

1.1 Overview of the Market 1.2 Scope of Report 1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining 3.2 Validation 3.3 Primary Interviews 3.4 List of Data Sources

4 Regenerative Medicine Market Outlook

4.1 Overview 4.2 Market Dynamics 4.2.1 Drivers 4.2.2 Restraints 4.2.3 Opportunities 4.3 Porters Five Force Model 4.4 Value Chain Analysis

5 Regenerative Medicine Market, By Deployment Model

5.1 Overview

6 Regenerative Medicine Market, By Solution

6.1 Overview

7 Regenerative Medicine Market, By Vertical

7.1 Overview

8 Regenerative Medicine Market, By Geography

8.1 Overview 8.2 North America 8.2.1 U.S. 8.2.2 Canada 8.2.3 Mexico 8.3 Europe 8.3.1 Germany 8.3.2 U.K. 8.3.3 France 8.3.4 Rest of Europe 8.4 Asia Pacific 8.4.1 China 8.4.2 Japan 8.4.3 India 8.4.4 Rest of Asia Pacific 8.5 Rest of the World 8.5.1 Latin America 8.5.2 Middle East

9 Regenerative Medicine Market Competitive Landscape

9.1 Overview 9.2 Company Market Ranking 9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview 10.1.2 Financial Performance 10.1.3 Product Outlook 10.1.4 Key Developments

11 Appendix

11.1 Related Research

Request Customization of Report @ https://www.verifiedmarketresearch.com/product/global-regenerative-medicine-market/?utm_source=FSA&utm_medium=003

Highlights of Report

About Us:

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne Fernandes Call: +1 (650) 781 4080 Email: [emailprotected]

Originally posted here:
Regenerative Medicine Market Business Scenario 2020 | SWOT Analysis by Major Players- Organogenesis Osiris Therapeutics, Vericel Corporation, Stryker...

Read More...

JPM: Biotech, VC execs on where the industry should look beyond cancer – FierceBiotech

January 21st, 2020 8:46 am

SAN FRANCISCOOncology is clearly a major medical and societal issue: a major killer that, while predominately affecting the older population, can strike the young through a mixture of environmental factors or a genetic lottery. Its no wonder we struggle to even call it by its name, preferring just the "big C."

Biopharma has acted accordingly over the years and spent billions (and made many more billions) developing new oncology therapies, with the media and political focus falling on cancer drugs far more acutely than any other area, whether that be over pricing (the current average cost of a new cancer drug in the U.S. is around $100,000), effectiveness/safety or rejection from healthcare gatekeepers, such as the National Institute for Health and Care Excellence in England.

But cancer is only one disease area: Heart disease is the biggest killer in the U.S., yet there are very few new and innovative CV drugs out there, with influenza complications, such as pneumonia, Alzheimers disease, stroke and diabetes complications all leading causes of death in the U.S. There has been a war on cancer, but not a war on stroke.

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

There is also the growing threat of antimicrobial resistance, where decades-old antibiotics are ceasing to work against common forms of bacteria as they evolve; this, coupled with the fact that most life science companies arent working on a next generation of antibiotics (R&D costs are high with little or no ROI), means we could very well be facing a new surge in deaths in the future from once preventable diseases and infections.

At the J.P. Morgan Healthcare Conference in San Francisco this week, we at FierceBiotech wondered what the industry was doing about this and asked a range of life science C-suite execs: What therapeutic areas beyond cancer are most important to the industry now? both in terms of unmet need as well as where there is some real innovation.

Jim Robinson, chief operating officer at Paragon Biosciences, said: I spent 10 years in oncology, so I understand that point. Still, the biggest issue we face today that has to be figured out is Alzheimers. Looking at the aftermath, its scaryits going to be trillions of dollars in 20 short years in terms of the expense treating patients with Alzheimers. In 20 short years, I might be one of those patients!

I think its been a vast wasteland of failure. Im hoping something comes about before Im 70 to allow us to treat it. Whether the industry is willing to shift more resources to pursue treatments or not remains to be seen, especially after the latest failures. I dont know if the industry will shift to Alzheimers or more CNS treatments associated with cognition, but Im hoping.

Oncology good news is when the industry shifted and thousands of drugs moved through development. We see a significant transformation in certain cancers. If the incentive or the approach from a regulatory pathway that shifts incentives to research in Alzheimers, we will find some answers.

The biotechs CEO, Jeff Aronin, who is also CEO of Paragon Capital Partners, echoed this need for answers. I have a focus there with one of our companies, but in general, I would answer a little broader, he explained. Ive been involved in CNS drug development for a very long time and remember the 90s, which they called the decade of the brain, but we really didnt make a lot of advances in neuroscience and psychiatry that we thought we would have.

I think over the next few years is where we are really going to see many medicines approved. We have learned so much more and advancing in many different areas. In neuroscience and psychiatry, I would add theyre also an area of tremendous cost to the healthcare system and we still dont have a lot of great solutions, whether its Alzheimers or any of the neuropsychiatry areas were working in.

BioNTechs Sean Marrett also saw Alzheimers and other neuroscience areas, such as Parkinsons disease, as still major and unmet issues, as well as multiple sclerosis, which has seen great strides but still needs work.

Alzheimers is certainly a major issue, but also one that is more entrenched in the west: We live longer and are therefore more susceptible to diseases associated with aging.

Lyndra Therapeutics CEO Patricia Hurter asked us whether we meant our question in relation to the developed world or the developing world? We asked her two cents on both.

Women in Africa either get pregnant or get HIV, she said starkly. Their economic prospects are horrendous. It means their childrens economic prospects are horrendous. Were working with Gilead on HIV prophylaxis and on an oral birth control. Eventually, when the drugs are potent enough, we could do a once-a-month pill of each. To have them in one capsulethat would be fabulous. That would be transformative for developing countries.

For America, I think so many things like hypertension and diabetes are a chronic epidemic and people are having bad health outcomes [that could be avoided] if they took well proven drugs in an adherent way. Its an adherence issue. Theyre not feeling sick so they dont take the medicine. But in fact, it is still progressing [it, referring to stuff like hypertension, NASH that progressively gets worse without you feeling sick until its advanced].

It leads to unnecessary hospitalizations. If we could combine modern methods of distribution that a poly-pill combination that a person neededonce a week they would take one thing to keep them from progressing.

Karuna Therapeutics CEO Steve Paul also pointed to suicide rates that keep going up, whereas in certain types of cancer and cardiovascular disease theyve started tracking down.

And, finally, Westlake Village Biopartners Managing Partner Sean Harper said: Because there are so many areas of unmet need, its hard to say just one therapeutic area or one modality. Its exciting: the cellular engineering thats going to result in the ability to do regenerative medicine type efforts is I think going to be the next really amazing sort of thing.

With the fact that you can manipulate human cells now the way you can, and make multiple difficult edits to engineer things out of them and so on, that is just a new frontier. There are a lot of settings where you can just imagine what that can do. Its not 100 years away. Its now. Its happening already, people are doing it. I think that, to me, is the most exciting area.

See the original post:
JPM: Biotech, VC execs on where the industry should look beyond cancer - FierceBiotech

Read More...

Global Regenerative Medicine Market expected to Growth at an impressive CAGR during the period of 2020-2025 – Fusion Science Academy

January 21st, 2020 8:46 am

This report focuses on global Vision Sensor status, future forecast, growth opportunity, key market, and key players. The study objectives are to present the Vision Sensor development in the United States, Europe, and China.

In 2018, the global Vision Sensor market size was million US$ and it is expected to reach million US$ by the end of 2025, with a CAGR of during 2019-2025.

The report also summarizes the various types of Vision Sensor market. Factors that influence the market growth of particular product category type and market status for it. A detailed study of the Vision Sensor Market has been done to understand the various applications of the usage and features of the product. Readers looking for scope of growth with respect to product categories can get all the desired information over here, along with supporting figures and facts.

Get Global Vision Sensor sample copy of thisreport https://www.lexisbusinessinsights.com/request-sample-75861

Top Key players: Festo, BALLUFF, BANNERENGINEERINGCORP, CARLOGAVAZZI, COGNEX, DatalogicAutomation, di-soric, HEXAGONMANUFACTURINGINTELLIGENCE, ifmelectronic, ipfelectronicgmbh, LaetusGmbH, LMITechnologies, OMRON, Optekelectronics, Pepperl+FuchsGmbH, SENSOPART, Servo-Robot, SICK, TelemecaniqueSensors, TURCK, VisionComponents, and wenglorsensoricGmbH

Vision Sensor Market: Regional Segment Analysis.

This report provides pin-point analysis for changing competitive dynamics. It offers a forward-looking perspective on different factors driving or limiting market growth. It provides a five-year forecast assessed based on how the Vision Sensor Market is predicted to grow. It helps in understanding the key product segments and their future and helps in making informed business decisions by having complete insights of market and by making an in-depth analysis of market segments.

Key questions answered in the report include:

What will the market size and the growth rate be in 2026?

What are the key factors driving the Global Vision Sensor Market?

What are the key market trends impacting the growth of the Global Vision Sensor Market?

What are the challenges to market growth?

Who are the key vendors in the Global Vision Sensor Market?

What are the market opportunities and threats faced by the vendors in the Global Vision Sensor Market?

Trending factors influencing the market shares of the Americas, APAC, Europe, and MEA.

The report includes six parts, dealing with:

1.) Basic information;

2.) The Asia Vision Sensor Market;

3.) The North American Vision Sensor Market;

4.) The European Vision Sensor Market;

5.) Market entry and investment feasibility;

6.) The reports conclusion.

All the research report is made by using two techniques that are Primary and secondary research. There are various dynamic features of the business, like client need and feedback from the customers. Before (company name) curate any report, it has studied in-depth from all dynamic aspects such as industrial structure, application, classification, and definition.

The report focuses on some very essential points and gives a piece of full information about Revenue, production, price, and market share.

Vision Sensor Market report will enlist all sections and research for every point without showing any indeterminate of the company.

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward-looking perspective on different factors driving or restraining the market growth

It provides a six-year forecast assessed based on how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making an in-depth analysis of market segments

TABLE OF CONTENT:

1 Report Overview

2 Global Growth Trends

3 Market Share by Key Players

4 Breakdown Data by Type and Application

5 United States

6 Europe

7 China

8 Japan

9 Southeast Asia

10 India

11 Central & South America

12 International Players Profiles

13 Market Forecast 2019-2025

14 Analysts Viewpoints/Conclusions

15 Appendix

Get Global Vision Sensor Complete Brochure @ https://www.lexisbusinessinsights.com/request-sample-75861

About Us:

Statistical surveying reports is a solitary goal for all the business, organization and nation reports. We highlight a huge archive of most recent industry reports, driving and specialty organization profiles, and market measurements discharged by rumored private distributors and open associations. Statistical surveying Store is the far-reaching gathering of market knowledge items and administrations accessible on air. We have statistical surveying reports from a number of driving distributors and update our gathering day by day to furnish our customers with the moment online access to our database. With access to this database, our customers will have the option to profit by master bits of knowledge on worldwide businesses, items, and market patterns

Contact Us:

Lexis Business Insights

Aaryan

(Director- Business Development)

US: +1 210 907 4145

UK: +44 7880 533158

[emailprotected]

http://www.lexisbusinessinsights.com

We are a vibrant market research company which is focused on catering to more and more people day by day. Our research company is one of a few reliable market research report companies in todays date.

See the original post here:
Global Regenerative Medicine Market expected to Growth at an impressive CAGR during the period of 2020-2025 - Fusion Science Academy

Read More...

Sports Medicine Market to Expand at a Healthy Growth Rate in the Coming Years – Press Release – Digital Journal

January 21st, 2020 8:46 am

North America is expected to hold a significant share in the sports medicine market during the forecast period

This press release was orginally distributed by SBWire

Northrook, IL -- (SBWIRE) -- 01/20/2020 -- Growth in the sports medicine analysis market can be attributed to factors such as the increasing incidence of sports injuries, continuous influx of new products & treatment modalities, and developments in the field of regenerative medicine. On the other hand, the high cost of implants and other devices and the dearth of skilled professionals are expected to limit market growth to a certain extent during the forecast period.

What the Market Looks Like?

Predicted to grow at a CAGR of 6.5% during the forecast period, the global sports medicine market is estimated to reach USD 9.1 Billion by the end of 2024. Factors such as the rising popularity of sports and physical activity, increasing awareness regarding the prevention & treatment of sports injuries, and growing investments in sports medicine are driving the North American market.

On the basis of products, the sports medicine market is segmented into body reconstruction products (fracture & ligament repair products, arthroscopy devices, implants, prosthetics, orthobiologics), body support & recovery products (braces & support, physiotherapy equipment, and compression clothing), and accessories. The body support & recovery products segment is expected to witness the fastest growth during the forecast period. Products such as braces, supports, and physiotherapy equipment are required before and after procedures involving reconstruction. Thus, the demand for these devices is growing due to the increasing number of sports injuries globally.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=751

Sports medicine is widely used for the prevention of sports injuries as well as for the cure, recovery, and rehabilitation of athletes. The sports medicine applications market is segmented into knee injuries, shoulder injuries, foot & ankle, elbow & wrist, back & spine, hip & groin, and other injuries. The knee injuries segment held the largest share of the market in 2018, a trend that is expected to continue during the forecast period. The large share of this segment can be attributed to the fact that a large number of knee injuries are recorded across major sports, globally, accounting for approximately 40% of all injuries due to sports.

What Drives the Market?

The growth of the global market for sports medicine is primarily influenced by the following factors:

- Increasing Incidence of Sports Injuries - Continuous Influx of New Products and Treatment Modalities - Developments in the Field of Regenerative Medicine

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=751

Geographical growth scenario of Sports Medicine Market:

Geographically, North America is expected to dominate the global sports medicine market in 2018, while the Asia Pacific region is expected to register the highest CAGR during the forecast period.

The high growth in this region can be attributed to the growth of the sports industry and overall participation in sports. Sporting events such as the 2008 Beijing Olympics, 2018 Winter Olympics in Korea, and the upcoming 2020 Summer Olympics in Japan have increased the level of interest in sports in Asia.

Leading market players and strategies adopted:

The major players operating in the sports medicine market include Arthrex, Inc (US), Smith & Nephew plc (UK), and Stryker Corporation (US). Other players involved in this market include Breg Inc. (US), DJO Global, Inc. (US), Mueller Sports, Inc. (US), Wright Medical Group N.V. (US), Medtronic (Ireland), RTI Surgical (US), Performance Health International Limited (US), KARL STORZ (Germany), and Bauerfeind AG (US).

Request Bundle Reports: https://www.marketsandmarkets.com/RequestBundleReport.asp?id=751

About MarketsandMarketsMarketsandMarkets provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Shelly SinghMarketsandMarkets INC.630 Dundee RoadSuite 430Northbrook, IL 60062USA : 1-888-600-6441sales@marketsandmarkets.com

For more information on this press release visit: http://www.sbwire.com/press-releases/sports-medicine-market-to-expand-at-a-healthy-growth-rate-in-the-coming-years-1271600.htm

Original post:
Sports Medicine Market to Expand at a Healthy Growth Rate in the Coming Years - Press Release - Digital Journal

Read More...

Stem Cell Assay Market to Expand at a Healthy CAGR of XX% Between and 2017 2025 Dagoretti News – Dagoretti News

January 21st, 2020 8:46 am

In 2019, the market size of Stem Cell Assay Market is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.

In this report, 2019 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Stem Cell Assay .

This report studies the global market size of Stem Cell Assay , especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).

Request Sample Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=40&source=atm

This study presents the Stem Cell Assay Market production, revenue, market share and growth rate for each key company, and also covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. Stem Cell Assay history breakdown data from 2014 to 2019, and forecast to 2025.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global Stem Cell Assay market, the following companies are covered:

growth drivers and lists down the major restraints. Additionally, the report gauges the effect of Porters five forces on the overall stem cell assay market.

Global Stem Cell Assay Market: Key Market Segments

For the purpose of the study, the report segments the global stem cell assay market based on various parameters. For instance, in terms of assay type, the market can be segmented into isolation and purification, viability, cell identification, differentiation, proliferation, apoptosis, and function. By kit, the market can be bifurcated into human embryonic stem cell kits and adult stem cell kits. Based on instruments, flow cytometer, cell imaging systems, automated cell counter, and micro electrode arrays could be the key market segments.

In terms of application, the market can be segmented into drug discovery and development, clinical research, and regenerative medicine and therapy. The growth witnessed across the aforementioned application segments will be influenced by the increasing incidence of chronic ailments which will translate into the rising demand for regenerative medicines. Finally, based on end users, research institutes and industry research constitute the key market segments.

The report includes a detailed assessment of the various factors influencing the markets expansion across its key segments. The ones holding the most lucrative prospects are analyzed, and the factors restraining its trajectory across key segments are also discussed at length.

Global Stem Cell Assay Market: Regional Analysis

Regionally, the market is expected to witness heightened demand in the developed countries across Europe and North America. The increasing incidence of chronic ailments and the subsequently expanding patient population are the chief drivers of the stem cell assay market in North America. Besides this, the market is also expected to witness lucrative opportunities in Asia Pacific and Rest of the World.

Global Stem Cell Assay Market: Vendor Landscape

A major inclusion in the report is the detailed assessment of the markets vendor landscape. For the purpose of the study the report therefore profiles some of the leading players having influence on the overall market dynamics. It also conducts SWOT analysis to study the strengths and weaknesses of the companies profiled and identify threats and opportunities that these enterprises are forecast to witness over the course of the reports forecast period.

Some of the most prominent enterprises operating in the global stem cell assay market are Bio-Rad Laboratories, Inc (U.S.), Thermo Fisher Scientific Inc. (U.S.), GE Healthcare (U.K.), Hemogenix Inc. (U.S.), Promega Corporation (U.S.), Bio-Techne Corporation (U.S.), Merck KGaA (Germany), STEMCELL Technologies Inc. (CA), Cell Biolabs, Inc. (U.S.), and Cellular Dynamics International, Inc. (U.S.).

Request For Discount On This Report @ https://www.tmrresearch.com/sample/sample?flag=D&rep_id=40&source=atm

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Stem Cell Assay product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of Stem Cell Assay , with price, sales, revenue and global market share of Stem Cell Assay in 2017 and 2019.

Chapter 3, the Stem Cell Assay competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Stem Cell Assay breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.

Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.

Customize This Report @ https://www.tmrresearch.com/sample/sample?flag=CR&rep_id=40&source=atm

Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.

Chapter 12, Stem Cell Assay market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.

Chapter 13, 14 and 15, to describe Stem Cell Assay sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Go here to see the original:
Stem Cell Assay Market to Expand at a Healthy CAGR of XX% Between and 2017 2025 Dagoretti News - Dagoretti News

Read More...

How Doctors from Across the Globe Saved an Infant with Months to Live – Healthline

January 21st, 2020 8:45 am

USP18 deficiency is a rare genetic disorder that affects inflammation. It occurs in fewer than 1 in 1 million births.

A child with a rare genetic disorder called USP18 would normally be expected to survive for no more than a few weeks.

But thanks to the collaborative efforts of physicians and researchers in Saudi Arabia, France, and the United States, a young boy with this disease is now 3 years old and in remission.

USP18 deficiency is a rare genetic disorder that affects inflammation. It occurs in fewer than 1 in 1 million births.

In a report published earlier this week in The New England Journal of Medicine, members of this international team describe how they used supportive clinical care, rapid genetic diagnosis, and prompt treatment with a novel anti-inflammatory drug to keep the boy alive.

Such collaborative efforts are very important for managing rare disorders like USP18 deficiency, Dusan Bogunovic, PhD, co-corresponding author of the case report and an associate professor of microbiology and pediatrics at the Icahn School of Medicine at Mount Sinai in New York, told Healthline.

I dont think this can be stressed enough, he said.

Rare diseases by definition cannot be managed alone. Each requires expertise that very few people on the planet have, he continued.

Researchers in Bogunovics lab first described USP18 deficiency in 2016 as part of their work on rare inflammatory diseases in children.

They identified a very rare genetic mutation of the ubiquitin-specific peptidase 18 gene, which plays a role in regulating inflammation.

Mutations in this gene cause out of control inflammation that usually proves to be fatal in utero or shortly after birth.

Babies [with USP18 deficiency] present with what appears to be an infection but dont respond to antibiotics or antivirals, Bogunovic explained.

They have problems breathing. They have accumulation of fluid in the brain. They look like they are severely inflamed, he continued.

The boy in Saudi Arabia developed these problems in the first weeks of his life. He didnt recover after antibiotic and antiviral treatments.

After keeping him alive for months with supportive clinical care, physicians at King Saud University reached out to Bogunovic for help.

This was the start of a fruitful collaboration, in which experts across multiple institutions and countries worked together to rapidly develop a diagnosis and treatment plan.

To unravel the mystery of the boys symptoms, scientists conducted rapid genetic sequencing and protein testing.

These tests allowed the scientists to quickly identify a mutation in the USP18 gene that was interfering with protein function in the boys body.

Armed with this knowledge, they decided to try treatment with ruxolitinib. This oral drug belongs to a class of medications known as JAK inhibitors, which have potent anti-inflammatory effects.

After some trial and error, the boys treatment team found an effective dosage of the drug. Within 2 weeks, his symptoms began to quickly improve. Now, after 2 years of treatment, he remains symptom-free.

We showed that even with a disease like USP18 deficiency, sound clinical care and timely drug administration can rescue patients from what was previously considered a death sentence, Bogunovic said in a press release.

The teamwork between our two institutions and others around the world is a textbook case of science without borders, he added.

This case highlights the role that rapid genetic diagnosis can play in the management of not just USP18 deficiency, but also in the management of other rare genetic diseases.

To find the mutation that was responsible for the boys symptoms in Saudi Arabia, Bogunovics team used a next-generation method of genetic analysis known as whole exome sequencing.

Exome sequencing is a cost-effective DNA sequencing strategy that focuses on detecting genetic variants in the most critical regions of the human genome, the regions that contain genes and code for proteins, Stephen Montgomery, PhD, an associate professor of pathology and genetics at Stanford University, told Healthline.

This method relies on new technologies that allow scientists to rapidly sequence all of the bits of DNA that provide instructions for producing proteins. Those particular segments of DNA are known as exons. Together, they comprise a persons exome.

If a doctor or researcher wants to quickly sequence an individuals entire genome rather than just the exome, they can use a method known as whole genome sequencing.

Together these methods of rapid testing have revolutionized the diagnosis and management of rare genetic diseases.

Compared to more traditional methods of genetic sequencing, whole exome sequencing and whole genome sequencing are much less time consuming.

And although these tests arent cheap, they tend to be less expensive than the battery of specialist appointments and lab tests that patients might otherwise need to get to the bottom of a mysterious illness.

The way it used to work was, youd go see a specialist and they would order a test, and youd go see another specialist, and they would order a test and since there are over 10,000 genetic diseases, you can imagine that thats a lot of office visits, Dr. Stephen Kingsmore, president and CEO of Rady Childrens Institute for Genomic Medicine at Rady Childrens Hospital in San Diego, California, told Healthline.

Instead of that long diagnostic odyssey, doctors can now order a single sequencing test to check for every known genetic disease.

Instead of taking years to find out the rare genetic cause of a childs condition, you can now decode their genome in a day, Kingsmore said.

Make an immediate diagnosis, nip the disease in the bud, and get the appropriate treatment on board immediately, he said.

Here is the original post:
How Doctors from Across the Globe Saved an Infant with Months to Live - Healthline

Read More...

Treating the untreatable – News – Nature Middle East – Nature Middle East

January 21st, 2020 8:45 am

A rare, fatal genetic disease is treated with an existing immunotherapeutic drug.

Chest radiography after two months of ruxolitinib therapy showed sufficient improvement for weaning off of mechanical ventilation.The New England Journal of Medicine 2020 A three-year-old Saudi boy is in full remission from a fatal gene deficiency following treatment with a known immunotherapeutic drug. USP18 deficiency is an extremely rare genetic disorder that impairs the immune system, with prominent symptoms including respiratory failure, accumulation of fluid in the brain, and inflammation throughout the body.

We are in the renaissance period when it comes to rapid genetic diagnosis and experimental treatment of inherited disorders, says associate professor of paediatrics Dusan Bogunovic of the Icahn School of Medicine at Mount Sinai, New York. Now we know that USP18 deficiency is treatable with JAK inhibitors, if detected early.

In healthy individuals, the USP18 (ubiquitin-specific peptidase 18) gene codes for an enzyme that inhibits a part of the immune system called interferon signalling, curbing excessive inflammation. USP18 enzyme deficiency leads to abnormal inflammation across multiple tissues. The Saudi child was diagnosed with complete absence of USP18, and had been kept alive through extraordinary medical care by physicians in Saudi Arabia. Genetic and biochemical tests confirmed that oral administration of ruxolitinib, a Janus kinase (JAK) inhibitor drug used for treating certain bone marrow disorders, would be suitable for regulating the childs inflammation.

Within two months of ruxolitinib therapy, the boy was well enough to be weaned off of mechanical ventilation and is now, two years into therapy, in full remission of the clinical signs of the disorder. He is receiving follow-up treatment from an outpatient clinic and continues to grow normally, albeit with slower progress in his developmental milestones, the researchers say. The child will likely need to take ruxolitinib for the rest of his life.

Consultant paediatrician Abdullah Alangari at King Saud University, Saudi Arabia, says the study is a very good example of the value of international collaboration in helping critically ill patients and in advancing science.

Rare diseases cannot be managed alone, adds Bogunovic. Each requires expertise that very few people on the planet have, he says, commending the joint work by researchers in Saudi Arabia, France and the USA.

The clinical case study represents a significant milestone, says immunologist John Teijaro of Scripps Research Institute, USA, who was not involved in the study. This success should pave the way for utilizing ruxolitinib and other JAK inhibitors to treat additional autoimmune diseases where heightened interferon or cytokine signalling drive pathological manifestations.

Link:
Treating the untreatable - News - Nature Middle East - Nature Middle East

Read More...

Hackensack Meridian Health Center for Discovery and Innovation to Host Genomic Medicine Symposium – P&T Community

January 21st, 2020 8:45 am

NUTLEY, N.J., Jan. 17, 2020 /PRNewswire/ --Genomic medicine's groundbreaking treatments, and its future promise, will be the focus of a full-day symposium at the Hackensack Meridian Health Center for Discovery and Innovation (CDI) on Wednesday, February 19.

This emerging discipline for tailoring active clinical care and disease prevention to individual patients will be the focus of presentations given by eight experts from medical centers in the U.S.A. and Canada.

"The Genomic Medicine Symposium convenes a diverse group of scientific experts who help serve as a vanguard for precision medicine," said David Perlin, Ph.D., chief scientific officer and vice president of the CDI. "At the Center for Discovery and Innovation, we are working to make genomics a central component of clinical care, and we are delighted to host our peers and partners from other institutions."

"The event is one-of-a-kind," said Benjamin Tycko, M.D., Ph.D., a member of the CDI working in this area, and one of the hosts. "We are bringing together great minds with the hope it will help inform our planning for genomic medicine within Hackensack Meridian Health and inspire further clinical and scientific breakthroughs."

Cancer treatments, neuropsychiatric and behavioral disorders, cardiometabolic conditions, autoimmune disease, infectious disease, and a wide array of pediatric conditions are areas where DNA-based strategies of this type are already employed, and new ones are being tested and refined continually.

The speakers come from diverse medical institutions and will talk about a variety of clinical disorders in which prevention, screening, and treatment can be informed through genomic and epigenomic data.

Among the speakers are: Daniel Auclair, Ph.D., the scientific vice president of the Multiple Myeloma Research Foundation; Joel Gelernter, M.D., Ph.D., Foundations Fund Professor of Psychiatry and Professor of Genetics and of Neuroscience and Director, Division of Human Genetics (Psychiatry) at Yale University; James Knowles, M.D., Ph.D., professor and chair of Cell Biology at SUNY Downstate Medical Center in Brooklyn; Tom Maniatis, Ph.D., the Isidore S. Edelman Professor of Biochemistry and Molecular Biophysics, director of the Columbia Precision Medicine Initiative, and the chief executive officer of the New York Genome Center; Bekim Sadikovic, Ph.D., associate professor and head of the Molecular Diagnostic Division of Pathology and Laboratory Medicine at Western University in Ontario; Helio Pedro, M.D., the section chief of the Center for Genetic and Genomic Medicine at Hackensack University Medical Center; Kevin White, Ph.D., the chief scientific officer of Chicago-based TEMPUS Genetics; and Jean-Pierre Issa, M.D., Ph.D., chief executive officer of the Coriell Research Institute.

The event is complimentary, but registration is required. It will be held from 8 a.m. to 4:30 p.m. at the auditorium of the CDI, located at 111 Ideation Way, Nutley, N.J.

The event counts for continuing medical education (CME) credits, since Hackensack University Medical Center is accredited by the Medical Society of New Jersey to provide continuing medical education for physicians.

Hackensack University Medical Center additionally designates this live activity for a maximum of 7 AMA PRA Category 1 Credit TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For more information, visit https://www.hackensackmeridianhealth.org/CDIsymposium.

ABOUTHACKENSACKMERIDIAN HEALTH

Hackensack Meridian Health is a leading not-for-profit health care organization that is the largest, most comprehensive and truly integrated health care network in New Jersey, offering a complete range of medical services, innovative research and life-enhancing care.

Hackensack Meridian Health comprises 17 hospitals from Bergen to Ocean counties, which includes three academic medical centers Hackensack University Medical Center in Hackensack, Jersey Shore University Medical Center in Neptune, JFK Medical Center in Edison; two children's hospitals - Joseph M. Sanzari Children's Hospital in Hackensack, K. Hovnanian Children's Hospital in Neptune; nine community hospitals Bayshore Medical Center in Holmdel, Mountainside Medical Center in Montclair, Ocean Medical Center in Brick, Palisades Medical Center in North Bergen, Pascack Valley Medical Center in Westwood, Raritan Bay Medical Center in Old Bridge, Raritan Bay Medical Center in Perth Amboy, Riverview Medical Center in Red Bank, and Southern Ocean Medical Center in Manahawkin; a behavioral health hospital Carrier Clinic in Belle Mead; and two rehabilitation hospitals - JFK Johnson Rehabilitation Institute in Edison and Shore Rehabilitation Institute in Brick.

Additionally, the network has more than 500 patient care locations throughout the state which include ambulatory care centers, surgery centers, home health services, long-term care and assisted living communities, ambulance services, lifesaving air medical transportation, fitness and wellness centers, rehabilitation centers, urgent care centers and physician practice locations. Hackensack Meridian Health has more than 34,100 team members, and 6,500 physicians and is a distinguished leader in health care philanthropy, committed to the health and well-being of the communities it serves.

The network's notable distinctions include having four hospitals among the top 10 in New Jersey by U.S. News and World Report. Other honors include consistently achieving Magnet recognition for nursing excellence from the American Nurses Credentialing Center and being named to Becker's Healthcare's "150 Top Places to Work in Healthcare/2019" list.

The Hackensack Meridian School of Medicine at Seton Hall University, the first private medical school in New Jersey in more than 50 years, welcomed its first class of students in 2018 to its On3 campus in Nutley and Clifton. Additionally, the network partnered with Memorial Sloan Kettering Cancer Center to find more cures for cancer faster while ensuring that patients have access to the highest quality, most individualized cancer care when and where they need it.

Hackensack Meridian Health is a member of AllSpire Health Partners, an interstate consortium of leading health systems, to focus on the sharing of best practices in clinical care and achieving efficiencies.

For additional information, please visit http://www.HackensackMeridianHealth.org.

About the Center for Discovery and Innovation:

The Center for Discovery and Innovation, a newly established member of Hackensack Meridian Health, seeks to translate current innovations in science to improve clinical outcomes for patients with cancer, infectious diseases and other life-threatening and disabling conditions. The CDI, housed in a fully renovated state-of-the-art facility, offers world-class researchers a support infrastructure and culture of discovery that promotes science innovation and rapid translation to the clinic.

View original content to download multimedia:http://www.prnewswire.com/news-releases/hackensack-meridian-health-center-for-discovery-and-innovation-to-host-genomic-medicine-symposium-300989060.html

SOURCE Hackensack Meridian Health

Follow this link:
Hackensack Meridian Health Center for Discovery and Innovation to Host Genomic Medicine Symposium - P&T Community

Read More...

$29 million for new phase of international Alzheimer’s study Washington University School of Medicine in St. Louis – Washington University School of…

January 21st, 2020 8:45 am

Visit the News Hub

Research focuses on precisely how the disease develops in the brain

Anne Fagan, PhD, supervises staff scientist Matthew R. Amos as he analyzes samples for molecular signs of Alzheimer's disease. Fagan leads one arm of a long-running, international Alzheimers study aimed at understanding how the disease develops and progresses. Researchers at Washington University School of Medicine in St. Louis have received $29 million to continue the study known as the Dominantly Inherited Alzheimer Network for another five years.

For more than a decade, Washington University School of Medicine in St. Louis has led an international effort to better understand Alzheimers disease by studying people with rare genetic mutations that cause the disease to develop in their 50s, 40s or even 30s. The researchers have shown that the disease begins developing two decades or more before peoples memories begin to fade, as damaging proteins silently accumulate in the brain.

Now, the National Institute on Aging of the National Institutes of Health (NIH) has committed $29 million to support the effort known as the Dominantly Inherited Alzheimer Network (DIAN) for another five years, pending availability of funds. With the new funding, the network will add three new research initiatives to investigate more closely the changes that occur in the brain as the disease develops, which could lead to new ways to diagnose or treat Alzheimers.

The extraordinary accomplishments of the DIAN investigators and participants over the past decade have set the stage to understand the molecular changes that can cause Alzheimers disease, said DIAN director Randall J. Bateman, MD, the Charles F. and Joanne Knight Distinguished Professor of Neurology. The three new scientific projects will provide deep insights into how Alzheimers disease begins and progresses to dementia.

DIAN follows families with genetic mutations that all but guarantee that those who inherit the mutations will develop Alzheimers disease at young ages. While devastating for families, this genetic form of Alzheimers disease creates a rare opportunity for researchers to look for brain changes long before symptoms appear in people who carry such mutations, compared with their relatives who dont have the mutation.

Although the study follows only people with a rare genetic form of Alzheimers, its findings could apply to the millions of people living with the much more common late-onset Alzheimers, which appears after age 65. The brain changes that lead to memory loss and confusion are thought to be much the same in early- and late-onset Alzheimers.

Since the network was established in 2008, DIAN researchers have established 19 sites in eight countries representing North and South America, Europe, Asia and Australia with another five sites in four Latin American countries in the works. People from families with genetic forms of Alzheimers take part in observational studies to track changes to their brains over time. The network also has established a clinical trials unit to test investigational therapies to prevent or treat the disease.

Participants undergo assessments of their memory and thinking skills, provide DNA for genetic analysis, undergo brain scans, and give blood and cerebrospinal fluid so researchers can look for molecular signs of Alzheimers disease. With the help of such participants, researchers have begun to piece together a timeline of the brain changes that culminate in cognitive decline and dementia. First, the protein amyloid beta starts forming plaques in the brain up to two decades before symptoms arise. Later, tangles of tau protein form, and the brain begins to shrink. Only then do signs of confusion and forgetfulness appear.

In addition to supporting ongoing research efforts, the grant funds three new projects:

The study described in this press release is supported by the National Institute on Aging of the National Institutes of Health (NIH) under award number U19AG032438. The grant from the National Institute on Aging provides 95.4% of the funding for this study, with the remainder provided by the Alzheimers Association (3.3%) and a consortium of pharmaceutical companies (1.3%). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Washington University School of Medicines 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Childrens hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Childrens hospitals, the School of Medicine is linked to BJC HealthCare.

Continued here:
$29 million for new phase of international Alzheimer's study Washington University School of Medicine in St. Louis - Washington University School of...

Read More...

Immuno-oncology and personalised medicine to drive pharma in 2020 – European Pharmaceutical Review

January 21st, 2020 8:45 am

A survey of industry professionals states they expect immuno-oncology therapies and personalised medicines to continue to shape the pharmaceutical industry in the coming year.

An outlook report suggests that industry stakeholders expect immuno-oncology and personalised medicine to be the most impactful trends shaping the pharmaceutical sector in 2020.

Claire Herman, Global Director of Therapy Analysis and Epidemiology at GlobalData which compiled the research report, revealed: For the second consecutive year, our survey found that a majority of respondents believe that immuno-oncology or personalised medicine are the top trends to watch, with 40 percent and 34 percent, respectively, selecting them as the most impactful areas of investment and innovation.

Herman added: Immuno-oncology drugs have become increasingly well-established as a pillar of cancer care. This growth has been driven by regulatory approvals in a range of new indications, a slew of development and marketing partnerships and exploration of new combination treatment strategies.

a majority of respondents believe that immuno-oncology or personalised medicine are the top trends to watch

Fern Barkalow, GlobalDatas Senior Director of Oncology and Hematology, explained: As the mechanisms underlying the action of various immuno-oncology combination approaches become better elucidated, these drugs will gain further traction in the treatment paradigms of a variety of cancers in 2020, moving into earlier lines of therapy, as well as demonstrating success in those cold tumours previously resistant to immuno-oncology treatment.

A range of pipeline products entering late-stage development in the personalised medicine market during 2020 should also drive similar growth in this field. Industry experts suggest personalised medicine is set to hit milestones such as trial completion and regulatory filings.

Herman continued that there is great enthusiasm for a change in treatment strategies towards an individualised, patient-centric disease management approach. She also stated that while R&D in these areas has seen some setbacks, overall expectations are extremely high across a range of disease areas, from oncology to neurology to rare genetic disorders Investment in targeted therapeutics has been building for over a decade, with no end in sight.

See the rest here:
Immuno-oncology and personalised medicine to drive pharma in 2020 - European Pharmaceutical Review

Read More...

One Of The Most Common Ingredients In The Western Diet Has Been Found To Alter Genes In The Brain – IFLScience

January 21st, 2020 8:45 am

The use of soybean oil has increased dramatically over the last few decades, to the extent that is has become the most widely consumed edible oil in the US and other Western nations. However, its rise has coincided with an alarming escalation in metabolic conditions like diabetes, insulin resistance, and obesity, and a new study indicates that this may be down to the way that soybean oil causes genetic changes in the brain.

Previous research has shown that mice fed a diet that is high in soybean oil are much more likely to develop these conditions than rodents fed on other fats like coconut oil. Further studies hinted that the culprit may be linoleic acid, as mice that consumed soybean oil that had been modified to lack this key ingredient were spared many of these harmful effects.

To better understand how soybean oil produces these negative consequences, scientists decided to investigate its impact on the expression of genes in the hypothalamus, a brain region that regulates metabolism and a range of other essential processes.

Mice were split into groups, of which one received a diet that was high in normal soybean oil, another consumed a diet high in soybean oil that lacked linoleic acid, and another was fed on a diet rich in coconut oil.

Writing in the journal Endocrinology, the study authors explain that soybean oil was found to modify the expression of around 100 different genes in the hypothalamus, affecting processes such as metabolism, neurological disease, and inflammation.

Among the altered genes were some that are associated with schizophrenia, depression, and Alzheimers disease, although by far the most affected was a gene that codes for the production of a hormone called oxytocin.

Oxytocin is sometimes referred to as the love hormone as it promotes social bonding and feelings of euphoria, and disruptions to its functioning have been linked to depression and autism. However, it also plays a key role in regulating body weight and glucose metabolism, and mice fed on soybean oil were therefore found to suffer from glucose intolerance, while those fed on coconut oil had no such problems.

Furthermore, the oxytocin gene was affected equally in mice that consumed regular soybean oil and the version that lacked linoleic acid, suggesting that the removal of this ingredient does not protect against the harmful effects of soybean oil.

With linoleic acid ruled out as the main driver of these harms, the researchers turned their attention to another compound found in soybean oil called stigmasterol. A further group of mice were fed a diet rich in coconut oil that had been modified to contain high quantities of stigmasterol, to see if this caused similar genetic changes within the hypothalamus.

Yet no such genetic alterations were found in the hypothalamus of these mice, indicating that stigmasterol is not to blame for the dangers of soybean oil.

Future research will now need to focus on determining which ingredient is responsible for these genetic changes, although study author Poonamjot Deol of the University of California, Riverside says that while many questions remain unanswered, some very concrete statements can be made off the back of this study.

"If there's one message I want people to take away, it's this: reduce consumption of soybean oil," she said in a statement.

Read more:
One Of The Most Common Ingredients In The Western Diet Has Been Found To Alter Genes In The Brain - IFLScience

Read More...

CCMB to host an Indo-US workshop on the topic of genetic diseases – BPhrm Dv

January 21st, 2020 8:45 am

Centre for Cellular and Molecular Biology has brought the researchers together from both the United States and India, to work together in order to understand genetic diseases and their basis, among some other ethnic populations from other parts of the world to work for the workshop on Human Diversity and Health Disparities. This three days workshop started this Thursday.

Researchers will be deliberating on the topics of genetic and also the epigenetic basis of the various forms of diabetes, cancer, neurological and also heart diseases in USA and in South Asia during the meet-ups. There will be also be a focused and a detailed discussions on personalized medicine and their advancements in the field of technologies to make its access possible for the nations.

Dr Keshav Singh, from the University of Alabama, Birmingham and Dr Thangaraj from CCMB, who were the Co-convenors of the meeting stated that the existing data on the genetic diseases that we have at this moment, is mostly based on the European populations and for the personalized medicine for such diseases to progress, it is important to understand these population and their specific genetics.

The workshop is currently being attended by almost 200 researchers mostly from India and US, where many of them are PhD scholars from promising universities, research institutes, hospitals and the life science companies that are based in both India and in the USA.

Rakesh Mishra, CCMB director said that the Variation in population, the differential susceptibility to genetic diseases and their response to the currently applied treatment methods is known. With the genome information that we have, we can come up with a precise and a personalized approach for not just a more effective but also an economical approach to the curing of these diseases.

The Department of Infectious Diseases at Kasturba Medical College and Hospital was introduced by Zelalem Temesgen, Director of Mayo Clinic, HIV program, U.S., here on Monday. An official statement gave here said that talking subsequent to introducing the office, Dr.

Cardiovascular diseases are very common between humans at old age. In our modern day, it is becoming even more common due to the unhealthy lifestyle and diets being used. Accordingly, it is important to treat these diseases carefully to prevent

Metabolic disorders are an important and critical diseases that should be handled wisely. These diseases are important due to the side effects they have on the body that could be dangerous. The cause of metabolic diseases are hard to know.

Continue reading here:
CCMB to host an Indo-US workshop on the topic of genetic diseases - BPhrm Dv

Read More...

Color raises further $75-million funding – ITIJ

January 21st, 2020 8:45 am

Led by T. Rowe Funds and Viking Global Investors, the funding allowed Color to accrue a number of new partners, which now comprise Apple, Verily, Northshore University HealthSystem,the Teamsters Health and Welfare Fund of Philadelphia and Vicinity, and Sanford Health.

Color has also announced that it is now working alongside not-for-profit healthcare system Sanford Health to build on its Imagenetics genomics programme, which will, in turn, allow Sanford Health to embed genetic medicine directly into primary care, as well as to implement Colors digital tools to engage patients and streamline clinical reporting within its facilities.

Caroline Savello, Vice-President of Commercial for Color,commented: "In the last 18 months, we saw a huge acceleration with institutions around the world and across every type of player in the health ecosystem whether its hospitals or health systems, large-scale research programmes, payers, care delivery or employers who want to change the care delivery model for their population by understanding genetics across the population.

Continued here:
Color raises further $75-million funding - ITIJ

Read More...

Foundation Medicine touts concordance ahead of FDA ruling on liquid biopsy test – MedCity News

January 21st, 2020 8:45 am

A diagnostics subsidiary of Swiss drugmaker Roche has filed for approval of its liquid biopsy test and anticipates a Food and Drug Administration ruling in the first half of this year.

In an interview at the J.P. Morgan Healthcare Conference in San Francisco, Foundation Medicine CEO Cindy Perettie said the company filed for FDA approval of the FoundationOne Liquid test at the end of December. The approval would include companion diagnostics claims, as well as claims for microsatellite instability and blood tumor mutation burden. The company anticipates that the test would be covered under the National Coverage Determination for next-generation sequencing, rather than there being a need to obtain a new NCD. The company applied for approval in parallel with its biopharma partners, though Perettie declined to name them.

In October, the company presented data from the Phase II/III BFAST study which is enrolling 580 patients with non-small cell lung cancer on people receiving Roches drug Alecensa (alectinib), a drug that targets ALK fusions, a genetic driver of NSCLC. Among 2,219 screened and 2,188 whose tests yielded blood-based next-generation sequencing results, 5.8% were found to have ALK fusions. The overall response rate for patients in the study who received Alecensa was 87.4%, which investigators wrote resulted in a high response rate and clinical benefit among patients receiving the drug and validated liquid biopsys clinical utility in ALK fusion-positive NSCLC.

Having that concordance gives us a lot of confidence, Perettie said, referring to the ability of liquid biopsy to detect mutations at a rate comparable to what has been found before.

Although BFAST was not specifically designed to show head-to-head concordance with tissue biopsy, research has indicated that ALK fusions are present in 4-6% of NSCLC cases.

The study is also enrolling patients who receive Rozlytrek (entrectinib), an inhibitor of NTRK fusions, which are also genetic drivers of cancers, among other drugs.

Concordance is a crucial consideration with liquid biopsy because, while significantly less cumbersome than tissue biopsy, it of course would defeat the purpose of using liquid biopsy if patients who have undergone it nevertheless must still undergo tissue biopsy as well.

Photo: ImagesBazaar, Getty Images

Link:
Foundation Medicine touts concordance ahead of FDA ruling on liquid biopsy test - MedCity News

Read More...

Gold visa for Scientific Medal winners in the UAE – Gulf News

January 21st, 2020 8:45 am

The Medal for Scientific Distinguishment aims at encouraging scientific competencies in the UAE. Photo for illustrative purpose only. Image Credit: COURTESY EIAST

Dubai: The Mohammed bin Rashid Academy of Scientists (MBRAS) has announced the list of finalists for the third round of the Mohammed bin Rashid Medal for Scientific Distinguishment. The five finalists include scientists and scholars who have made a significant scientific contribution.

Celebrating and encouraging scientific competencies in the UAE, the medal allows scientists to showcase their capabilities by leveraging the wide array of opportunities offered by cutting-edge technologies. This will enable them to develop vital sectors and support advanced sciences in order to come up with innovative solutions to current and future challenges and harness such solutions to serve humanity and build a better world for future generations.

The winners of the third round of the Mohammed bin Rashid Medal for Scientific Distinguishment will be announced in February 2020, and will be granted the UAE Gold Visa along with their family members.

Ultimate goal

Sarah bint Yousif Al Amiri, UAE Minister of State for Advanced Sciences, said the UAE Government seeks to provide a nurturing environment for scholars of great scientific acheivements as reflected in the vision of His Highness Sheikh Mohammed bin Rashid Al Maktoum, UAE Vice President, Prime Minister and Ruler of Dubai. She noted that the ultimate goal is to engage talents and competencies to further develop sciences and scientific research, which will also achieve the objectives of the UAE Vision 2021, the National Advanced Sciences Agenda 2031 and the UAE Centennial Plan 2071.

- Sarah bint Yousif Al Amiri, UAE Minister of State for Advanced Sciences

The Mohammed bin Rashid Medal for Scientific Distinguishment reflects the keenness of the UAE Government to create a supporting environment for advanced sciences in the UAE, and to leverage innovative ideas and capabilities in its attempt to build the future and support the countrys evolution towards a sustainable and knowledge-based economy. This can be attained by extending support to the scientific and research movement and nurturing a generation of scientists and researchers who can utilize the latest innovations in science and technology to serve society and enhance the UAEs status as a global lab for future technologies, she said.

Granting the golden visa to winners of the Mohammed bin Rashid Medal for Scientific Distinguishment paves the way towards creating a stimulating environment conducive to advancement in various scientific research and knowledge fields. The move also underpins the UAEs approach to support development efforts, attract accomplished talents, competencies and researchers and encourage them to contribute to the UAEs overall economic growth and promote its leading position as a hub for scientists, innovators and researchers, she added.

Rigorous process

The Mohammed bin Rashid Medal for Scientific Distinguishment finalists were chosen from a long list of nominees from Khalifa University, UAE University, New York Abu Dhabi University, University of Sharjah, American University of Sharjah, Gulf Medical University in Ajman and Dubai Police. The finalists were evaluated by a specialised committee that included a group of top scientists and experts from different scientific fields from the National Academies of Sciences, Engineering, and Medicine in the United States.

A panel from the Emirates Scientists Council also interviewed each of the nominees. The panel included: Sarah bint Yousif Al Amiri, UAE Minister of State for Advanced Sciences and Chairperson of the Emirates Scientists Council; Dr Arif Sultan Al Hammadi, Director and the Executive Vice President of Khalifa University of Science Technology; and Professor Dr Ghaleb Ali Al Hadrami Al Breiki, Acting Vice Chancellor for Academic Affairs & Provost of UAE University.

Strict criteria

Nomination for the Mohammed bin Rashid Medal for Scientific Distinguishment is based on a set of strict criteria. Eligible candidates must be renowned scientists whose research has had a positive impact on the UAE and is aligned with the countrys vision. They must be active members in the UAE scientific community and have showcased a recognizable commitment to the development of young scientists and researchers through knowledge transfer. They must also be experts and a reference in their scientific field, both locally and internationally.

The Mohammed bin Rashid Medal for Scientific Distinguishment covers advanced research in several scientific disciplines, like Aerospace Engineering, Agricultural Biotechnology, Biology, Chemical Engineering, Civil Engineering, Clinical Medicine, Computer and Information Sciences, Earth and Environmental Sciences, Electrical Engineering, Food Sciences, Health Sciences, Material Engineering, Mechanical Engineering, Nanotechnology, Petroleum Engineering, and Physics.

Khalifa University accounted for 35 per cent of the finalists, UAE University 26 per cent and New York Abu Dhabi University 22 per cent.

Evaluation stages

The evaluation process for the Mohammed bin Rashid Medal for Scientific Distinguishment consisted of three stages. In the first stage, registration for the submission of applications from nominees was opened, allowing UAE-based scientists to participate, as well as receiving nominations from universities and research institutions. Nominees were evaluated based on the Medals initial criteria, notably specialisation, years of experience, application of scientific output and global impact of research.

In the second stage, nominees were evaluated by an international panel consisting of leading experts by looking at the nominees global impact on their respective fields.

The third stage consisted of final interviews conducted by the Emirates Scientists Council to assess the role of the nominated scientists/researchers and their contributions to scientific research in the UAE, as well as the extent to which their contributions are aligned with the National Advanced Sciences Agenda.

The finalists

Ehab El-Saadany

Director of Advanced Power and Energy Research Centre and a professor in the Electrical Engineering and Computer Science Department at Khalifa University of Science and Technology and Adjunct Professor at the ECE Department, University of Waterloo, Canada, he is the author of more than 420 top tier international journals and conferences publications with three US patents.

Professor El-Saadany helped 26 PhD and 20 Masters students graduate and supervised over 20 Postdoctoral fellows and visiting professors. He raised over $13 million in research funds from different federal, provincial and industrial entities internationally and nationally.

Rashid K. Abu Al-Rub

He is the Chair of Aerospace Engineering Department and the Director of Digital and Additive Manufacturing Centre at Khalifa University of Science and Technology. His primary research field is the development of macro-mechanics-based constitutive models and computational tools, as well as digital design, additive manufacturing and 3D printing.

He has published one book and over 300 publications in archival journals, book chapters and conference proceedings. He is responsible for a budget of more than $30 million and was selected in 2007 among nine leading scientists in the US by National Science Foundation and Department of Energy. He is one of the members of the US National Science Foundation - International Institute for Multifunctional Materials for Energy Conversion.

Lourdes Vega

He is the Director of the Research and Innovation Centre on CO2 and Hydrogen (RICH Centre) at Khalifa University and a Professor in Chemical Engineering with academic positions in the USA (University of Southern California, Cornell University); Spain (University of Sevilla, Universitat Rovira I Virgili, National Research Council of Spain); and the UAE.

Her work has been directed towards the combination of fundamental and applied research focused on sustainable processes and products. These include recent works on new refrigerants, water treatment, removal of contaminants and CO2 capture and utilisation. She is the author of more than 200 scientific papers and five patents, and she has raised more than $50 million as principal researcher grants. She serves as an editorial board member in five scientific journals and five international conference committees.

Bassam Ali

He is the Leader of the Molecular and Genomics Laboratory and Professor of Molecular and Genetic Medicine at UAE University. His research is focused on the identification of disease genes and mutations responsible for rare recessive disorders in Arab populations, and suggesting diagnostic and treatment means. He is the author of more than 80 articles in international prestigious journals and conferences.

He is on the editorial board of several international scientific journals and an expert reviewer in several biomedical journals. He also supervises 11 PhD and seven Masters students.

Mohammed ElMoursi

A Professor in the Electrical Engineering and Computer Science Department (EECS) at Khalifa University of Science and Technology, he specialises in renewable energy integration and smart grid development. He also leads Renewable Energy Integration at the Advanced Power and Energy Centre (APEC) research theme. He has two US patents and is the author of more than 140 papers published in international journals and conferences.

More:
Gold visa for Scientific Medal winners in the UAE - Gulf News

Read More...

Psychedelics have ‘extraordinarily potent’ anti-inflammatory power. Is there a place for them in mainstream medicine? – Genetic Literacy Project

January 21st, 2020 8:45 am

Research on psychedelics, which have been profoundly stigmatized, highly restricted, and tragically undeveloped for more than half a century, is stirring back to life and rekindling scientific, medical, and cultural interest in these compounds.

In 2008, a psychedelic compound related to the primary psychoactive alkaloid in peyote was discovered to exert extraordinarily potent anti-inflammatory effects at very low drug concentrationsin vitroandin vivo. Additional studies have confirmed the capacity of psychedelics to modulate processes that perpetuate chronic low-grade inflammation and thus exert significant therapeutic effects in a diverse array of preclinical disease models, includingasthma,atherosclerosis,inflammatory bowel disease, andretinal disease.

The U.S. Defense Advanced Research Projects Agency recently acknowledged thepotential of subperceptual psychedelics. To address the high rate of mental illness among active duty military personnel, DARPA aims to discover new compounds that can exert the rapid and robust antidepressant effects of psychedelics without the associated trip.

In the private sector,Compass Pathwaysis conducting Phase 2 trials of psilocybin for treatment-resistant depression.

The time has come to make psychedelics, once seen as out there substances, mainstream and boring again.

Read full, original post: Transforming psychedelics into mainstream medicines

Read this article:
Psychedelics have 'extraordinarily potent' anti-inflammatory power. Is there a place for them in mainstream medicine? - Genetic Literacy Project

Read More...

How fertile are you? ‘Ovarian reserve’ DTN tests that count your eggs offer mixture of control and misinformation – Genetic Literacy Project

January 21st, 2020 8:45 am

The direct to consumer testing market comes in many flavors these days, with companies like 23andMe dominating headlines with their genetic/ancestry tests targeting folks eager to learn more about themselves. Also joining the fray are tests designed to help women in theory, at least assess fertility by counting the number of eggs left in their ovaries.

Sounds like a great idea. Just one problem: egg counts may not be such a great indicator of fertility, according to the American College of Obstetricians and Gynecologists.

Still, that doesnt mean these tests have no value. A new study suggests they can empower women. And thats especially true for those who do not fit into the binary gender categories that health insurers may require for covering clinical versions of the test that cost ten times as much.

At-home tests for reproductive health for women have been around since the first home pregnancy kits hit the market in 1978. In 1989 came the first DIY ovulation predictor kits.

Tests to measure ovarian reserve how many eggs are left dont have the track record of these older tests. And they may not even be accurate for women who havent had difficulty conceiving or are taking birth control pills.

But do they still have value?

Moira A. Kyweluk, a fellow in the department of Medical Ethics and Health Policy at the Perelman School of Medicine at the University of Pennsylvania, decided to find out. She interviewed 21 women, of diverse backgrounds and circumstances, to tap their thoughts about direct-to-consumer (DTC) testing of ovarian reserve.

The women were recruited from social media, community center notice boards, and listservs, in Chicago during the first half of 2018. The findings appear in Social Science & Medicine.

Egg counters sold to consumers are part of the FemTech market. I view DTC testing as an entry point into what I term the new (in)fertility pipeline for women today. Because it is low cost and widely available, its reaching a larger demographic, people of diverse identities and backgrounds, and raising awareness of more advanced procedures and technologies like egg freezing, Dr. Kyweluk said in a news release.

But she questions the accuracy of these tests. Consumers continue to desire these tests, and theyre attractive, but they dont deliver on their promise.

The number of immature eggs in the two ovaries dwindles as a female ages.

Seven to eight million tiny undeveloped eggs are already present in a 20-week female fetus. That means, curiously, that a pregnant woman houses the cells that, when fertilized, will become her grandchild.

By birth, about a million oocytes remain, and that number is halved by puberty. Then by the start of menopause, around age 51, only 1,000 or so eggs remain. Over her lifetime, a woman ovulates 300 to 400 eggs.

Each egg occupies a chamber called a follicle. Each month between puberty and menopause, the largest egg pops out in response to a crescendo of luteinizing hormone thats ovulation. Meanwhile, anti-Mllerian hormone (AMH) suppresses release of the other, smaller eggs.

Its seemingly simple: The more AMH, the more eggs are left.

Measuring AMH is the basis of clinical tests used to predict ovulation in women undergoing in vitro fertilization (IVF) or egg freezing, presumably because theyve been unable to conceive. But the accuracy of AMH level to predict ovarian reserve among women who are fertile isnt known.

And so in 2019, the American College of Obstetricians and Gynecologists (ACOG) issued a statementthat consumer kits to measure AMH arent ready for prime time. The products are too variable and not standardized.

Serum anti-Mllerian hormone level assessment generally should not be ordered or used to counsel women who are not infertile about their reproductive status and future fertility potential, according to the statement. It includes a hypothetical case that illustrates misinformation about AMH testing:

A 26-year-old woman comes in for a wellness exam and the provider mentions the effects of aging on fertility. Im not ready to become pregnant now, but I would in the future. My friend recently took a blood test to check her egg count, so she knows how much longer she can wait to have a baby. Can I have that test?

If she meets criteria for infertility, her insurance might fork over a large part of the $1,500 cost for such a test. Thats why a DTC test kit that requires a pinprick of blood and costs $79 to $199, without requiring evidence of anything or an uncomfortable meeting with a health care provider, is an attractive alternative if it provides useful information.

The website for an ovarian reserve test kit from Modern Fertilitydoes comport with the ACOG statement.

Want kids one day? the opening page announces, like asking if you want to order a pizza. Women are invited to join a weekly egginar for information before they dive into the science that helps you do you.

Clicking ahead shows clear warnings that the test wont reveal infertility, but will indicate if a womans egg count is more or less than is average for her age. It sounds like peering into an egg carton to count whether it has all 12 expected eggs.

The test measures AMH, FSH (follicle stimulating hormone), and E2 (estradiol). Thats important to know, because a search for ovarian reserve testing on Amazon yielded first theEverlyWell ovarian reserve test egg quantity indicator, which measures only FSH not the important and telltale AMH.

The Modern Fertility test is also quite clear about what it can and cant do. A woman can discuss the results with her physician and ask about further testing and possibly pursuing IVF or egg freezing. Or, if she only has half a dozen in the egg carton analogy, she might expect to experience menopause sooner than shed thought.

Countering the ACOG statement is the LetsGetChecked product. The Ovarian Reserve Test is for anyone who is curious about their fertility status, according to the website. It costs $139.

The website for LetsGetChecked has a helpful list of conditions that can accelerate the whittling down of egg number, which a consumer can bring to a physician to explore further. These include polycystic ovary syndrome, chromosomal abnormalities such as Turners (XO) syndrome and fragile X, endometriosis, ovarian tumors, autoimmune disorders, and pelvic injuries. The woman would already know if shed had chemotherapy or radiation, which can damage eggs.

Dr. Kyweluk designed a study that would take a real-world view of the issues that might prompt a woman to take a DTC ovarian reserve test. Her paper is a series of vignettes.

The research differs from standard medical studies in that it is ethnographic, taking into account race and ethnicity, relationship status, insurance, sexual orientation, and socioeconomic group, because the reasons for seeking ovarian reserve testing go beyond biology. Dr. Kyweluk interviewed the women as they were deciding whether or not to take a test. She had a grant that paid for those who wanted to go ahead, using one company that provided access to a nurse practitioner to interpret findings.

Of the 21 participants, aged 21 to 45, 14 were white, 14 heterosexual, and 7 bisexual or queer. Three different scenarios of women seeking the DTC test indicate the variability of need.

Yvette was a 37-year-old African-American who had been trying with her husband to conceive for a decade. Their health insurance was quick to cover birth control, but assessing fertility, not so much.

When Yvettes ovarian reserve results were normal, the nurse suggested an ovulation predictor to better time intercourse and have her husband have a semen analysis.

Naomi was typical of a high-income, highly-educated white woman, who was stressing over whether she really wanted to have a baby. Would an ovarian reserve test indicate that it wasnt in the cards? Then she could stop thinking about it, or freeze eggs, which she could afford to do. Many women cant.

Josephine was 35 and African-American. A devout Catholic, she had just ended a long-term relationship. Her faith prompted her to ask, was I meant to be a parent? and she felt that the ovarian reserve test, if she had too few eggs, might reveal no.

Several women reported that taking the ovarian reserve test empowered them. Caroline, for example, was a 30-year-old queer white woman with a female partner. Medicaid had denied them coverage of any elective tests, and they didnt meet the diagnostic criteria for infertility because they were not a heterosexual couple.

The DTC test made me feel Im in control, like I can want some information, pay for it, and then get it. I didnt have to rely on a doctor to decide it was necessary for me to know this information. This is information that Ive wanted forever, Caroline told the researcher.

In one confusing case, the cisgender female partner (Breanne) of a transgender man (Tal) discovered, using a DTC test, that her ovarian reserve was quite low, something shed suspected from her age and irregular menstrual periods. The couple had planned to use a sperm donor and Breanne would carry the pregnancy. But if Breanne didnt have enough eggs, what would they do?

They had an idea. Did Tal still make eggs?

Hed been receiving testosterone injections for a decade as part of gender-affirming treatment and sported a full beard. But the DTC ovarian reserve test revealed he was still making the normal number of eggs for a cisgender woman his age. Hed carry the pregnancy!

But when Tal went to a clinical lab to repeat the ovarian reserve testing, the medical staff continually misunderstood their situation. Ultimately, Tal felt that inexpensive ovarian reserve testing was simply a foot in the door to other, more costly procedures, Dr. Kyweluk writes.

The bottom line: A DTC ovarian reserve test can give a woman a sense of control, but at the expense of an incomplete, confusing, or even meaningless clinical picture.

From a broader perspective, is egg counting an example of the medicalization of the range that is normal reproductive biology? Will it create the patients-in-waiting scenario that describes newborn screening that identifies genetic diseases well before they cause symptoms?

Steve Jobs is famous for inventing things that we didnt know we needed the iPod and then the iPhone. To paraphrase and take him a bit out of context, A lot of times, people dont know what they want until you show it to them.

Just as it took years for so many of us to realize that we couldnt live without smartphones, it will take time for data to accrue that improve the accuracy of DTC ovarian reserve tests in predicting infertility. Until then, it might be just one more thing to worry about.

Ricki Lewis is the GLPs senior contributing writer focusing on gene therapy and gene editing. She has a PhD in genetics and is a genetic counselor, science writer and author of The Forever Fix: Gene Therapy and the Boy Who Saved It, the only popular book about gene therapy. BIO. Follow her at her website or Twitter @rickilewis

See the original post:
How fertile are you? 'Ovarian reserve' DTN tests that count your eggs offer mixture of control and misinformation - Genetic Literacy Project

Read More...

Novel mutations in stem cells of young donors can be passed to recipients – BioNews

January 21st, 2020 8:45 am

20 January 2020

A new study suggests that rare harmful mutations in young healthy donors' stem cells can be passed on to recipients of stem cell transplants, potentially leading to health problems.

Stem cell transplants can be used to treat some blood disorders and cancers, such as acute myeloid leukaemia (AML), but can also have life-threatening complications such as cardiovascular problems and graft-versus-host disease (GvHD), where new immune cells from the donor attacks the patient's healthy cells.

'There have been suspicions that genetic errors in donor stem cells may be causing problems in cancer patients, but until now we didn't have a way to identify them because they are so rare,' said Dr Todd EDruley, Associate Professor of Paediatrics, Haematology and Oncology at Washington University School of Medicine, StLouis. 'This study raises concerns that even young, healthy donors' blood stem cells may have harmful mutations and provides strong evidence that we need to explore the potential effects of these mutations further.'Researchers analysed samples from patients with AML and their stem cell donors looking at 80 specific genes. The small pilot study identified at least one harmful genetic mutation in 11 of the 25 donors using an advanced sequencing technique. The donors ranged from 20 to 58 years old, with a median age of 26. Researchers later detected the harmful mutations present in donors within the recipients.

These extremely rare, harmful genetic mutations that are present in donors' stem cells do not cause any health problems to the donors, however, they may be passed on to the patients receiving stem cell transplants. Intense chemo- and radiation therapy is required prior to stem cell transplants and the immunosuppression given after the transplant unfortunately allows the rare mutation containing cells the opportunity to replicate quickly, which potentially can create health problems for the patients who receive them.

Co-author, Dr Sima TBhatt, Assistant Professor of Paediatrics, Haematology and Oncology also at Washington University, said 'Transplant physicians tend to seek younger donors because we assume this will lead to fewer complications. But we now see evidence that even young and healthy donors can have mutations that will have consequences for our patients. We need to understand what those consequences are if we are to find ways to modify them.'

The clinical implications of the findings need to be further studied. Dr Bhatt added: 'Now that we've also linked these mutations to GvHD and cardiovascular problems, we have a larger study planned that we hope will answer some of the questions posed by this one.'

See original here:
Novel mutations in stem cells of young donors can be passed to recipients - BioNews

Read More...

The three biggest challenges in lung cancer, and how researchers are tackling them – – pharmaphorum

January 21st, 2020 8:45 am

Despite new paradigm-shifting treatments, lung cancer remains a deadly disease and improving outcomes requires more than just drug research.

The new Lung Ambition Alliance launched in July last year has identified three major challengers that are inhibiting long-term survival worldwide: late diagnosis, few treatment advances for early-stage cancer, and disparity in cancer care both worldwide and within countries.

In Japan, where I practice medicine, almost a third of lung cancer patients are now living for five-years following diagnosis, explains Dr Tetsuya Mitsudomi, president of the International Association for the Study of Lung Cancer (IASLC) and co-founder of the Lung Ambition Alliance. This is in contrast to the global statistics where just about one in every five lung cancer patients is alive five years after diagnosis.

More pervasive, however, is that lung cancer is still blighted by stigma. The results of a recent survey conducted by Ipsos MORI, sponsored by the Lung Ambition Alliance, show that only one in five people (22%) disagree with the statement generally, patients with lung cancer have caused their illness through their lifestyle choices and behaviors. The stigma of lung cancer is problematic and could influence smokers to feel guilty, ignore symptoms, and delay talking to their doctor. Stigma also contributes to lower research funding for lung cancer.

Luckily, there are many organisations across the world passionate about tackling lung cancer. The IASLC alone has more than 7,500 members worldwide. Mitsudomi says that collaborations like the Lung Ambition Alliance which is a partnership between the IASLC, Guardant Health, the Global Lung Cancer Coalition (GLCC) and AstraZeneca are critical to bringing together distinct organisations, all with complementary experience in helping patients and healthcare professionals manage the disease.

We believe that together we can approach the problem of improving patient survival in a systematic way, he says, explaining the impetus behind the Alliance. And only through a collaborative approach will we be able to get better results.

Improving screening

The Alliances goal is to eliminate lung cancer as a cause of death the first step towards this being to double five-year survival by 2025.

Mitsudomi says the Alliance has identified three areas it wants to prioritise in order to achieve this goal.

The first is to improve lung cancer diagnosis by raising awareness of the strong evidence for screening and addressing the barriers to early detection, with continued improvements to the ease and reliability of diagnostics and contributions to a deeper understanding of disease progression.

Despite evidence that low dose CT (LDCT) can save lives, globally, few places have implemented screening programmes, he explains.

In the United States, the US Preventive Services Task Force (USPSTF) recommends annual screening for people at high risk of developing lung cancer; elsewhere, no such programmes exist, meaning we are missing the opportunity to diagnose asymptomatic people at a point when there is a potential for them to be cured.

Despite this, in a recent survey almost nine in ten people (87%) said they were in favour of implementing a national programme in their country to increase the detection of lung cancer in the early stages. Among them, nearly two in three (62%) declared that they are strongly in favor of it.

To this end, the Alliance has been supporting the Early Imaging Lung Confederation (ELIC) a new cloud-based screening registry designed to improve the multidisciplinary detection and management of early stage lung cancer, when there is still potential for a cure.

Despite evidence that low dose CT can save lives, globally, few places have implemented screening programmes we are missing the opportunity to diagnose asymptomatic people at a point when there is a potential for them to be cured.

Innovative medicines

The second area of priority is delivering innovative medicines, which Mitsudomi says can be improved by enabling widespread paradigm shifts to earlier intervention when there is greater potential for a cure.

The lung cancer treatment landscape continues to rapidly evolve, he adds. In recent years, were seeing targeted medicines, where therapies are matched to specific patients defined by the specific genetic changes in their lung cancers, improving outcomes for many. Were also seeing strides with the number of immunotherapies being utilised in the clinic, but we believe that we can do better.

Precision medicine may be even more effective if administered earlier in the course of the disease, so were prioritising the validation of surrogate endpoints and the identification of predictive biomarkers to accelerate the research of these medicines in patients where there is the potential for a cure, rather than just to moderately extend survival.

The Alliance also supports the Major Pathologic Response (MPR) Project for pre-operative drug therapy.

Were exploring whether a given innovative therapy, such as immunotherapy, before surgery prolongs survival of the patients, explains Mitsudomi.

The problem is, it takes a long time to know the final results if overall survival is used as an endpoint. Instead, several investigators have begun to use MPR, which is tentatively defined as the percentage of patients whose cancer cells die by more than 90% in the resected specimen, however the definition is not yet standardised.

The MPR Project is a collection of clinical trial data and research that can be used to validate surrogate endpoints and identify predictive biomarkers. These in turn will become an important resource to accelerate the development of next-generation treatments for an ever-expanding range of tumor types and genetic mutations.

Quality of care

Finally, the Alliance hopes to enhance quality of care by working with advocates and policymakers to deliver projects to address the challenges most urgent to patients on the local level, by improving coordination across the multidisciplinary team and by instilling the urgency to act.

The key problem here remains the high variations in lung cancer management around the world. Moreover, there can often be very specific local barriers to quality care that must be considered when developing patient centric solutions to address them.

The Alliance is hoping to tackle this through the recently-announced Initiatives in Lung Cancer Care (ILC2) grant programme, an open call inviting registered patient organisations with a focus on lung cancer, around the world, to submit proposals for projects that can potentially transform patient care and improve survival within their home countries.

Similarly, the Alliance is now supporting the Staging Project, which started in 1997 as a means to reduce the wide variations and disparities in lung cancer staging, which is critical when identifying appropriate treatments for patients.

Through this we are working to standardise international lung cancer staging guidelines and are using this information to guide the development of the 9th edition of the Tumour, Node and Metastasis (TNM) staging system, the most commonly used system for classifying the spread of lung cancer in individual patients, says Mitsudomi.

The magnitude of the challenge faced in tackling lung cancer can seem overwhelming at times, and its not a problem thats going to go away any time soon. But it is also clear that this is a disease that has the attention of thousands of incredibly motivated researchers, patient groups and HCPs who will stop at nothing to eliminate it.

See original here:
The three biggest challenges in lung cancer, and how researchers are tackling them - - pharmaphorum

Read More...

Page 716«..1020..715716717718..730740..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick